Trial Profile
Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics
- 27 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 27 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2011 Planned end date changed from 1 Jan 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.